Starting biologic early could save more than joints. In 329 RA pts, first-line anti-TNF reduced testing and hospitalization costs vs csDMARDs across Europe. Earlier targeted therapy pay off in outcomes and economics. @RheumNow #ACR25 Abstract#2271 https://t.co/zZ32CpT36d